Search

Displaying results 3931 - 3940 of 4692 in total
  1. Drug

    Seliciclib

    go.drugbank.com/drugs/DB06195
    Investigational

    Developed by Cyclacel, seliciclib is being researched for the treatment of non-small cell lung cancer (NSCLC), leukemia, HIV infection, herpes simplex infection, and the mechanisms of chronic inflammation

  2. Drug

    Candoxatrilat

    go.drugbank.com/drugs/DB11623
    Experimental

    A dicarboxylic acid monoamide obtained by formal condensation between the amino group of cis-4-aminocyclohexanecarboxylic acid and the cyclopentanecarboxylic acid group of 1-[(2S)-2-carboxy-3-(2-methoxyethoxy

  3. Drug

    Sifalimumab

    go.drugbank.com/drugs/DB12773
    Investigational

    Sifalimumab may suppress the abnormal immune activity associated with lupus by binding to multiple interferon-alpha subtypes seen in the serum of lupus patients.

  4. Drug

    PMI-001

    go.drugbank.com/drugs/DB05730
    Experimental

    PMI-001 is a stand-alone, disease-modifying, anti-rheumatic drug (DMARD) being developed by Phytomedics Inc.

  5. Drug

    LU-31130

    go.drugbank.com/drugs/DB05828
    Experimental

    LU-31130 is a rapid acting therapy developed by H. Lundbeck A/S to treat Psychosis, Schizophrenia and Schizoaffective Disorders.

  6. Drug

    anti-alpha5Beta1-integrin antibody

    go.drugbank.com/drugs/DB05870
    Experimental

    The integrin alpha5beta1 has been shown to play a critical role during angiogenesis. anti-alpha5beta1 integrin antibody inhibits angiogenesis, including vessel formation induced by vascular endothelial

  7. Drug

    GRAd-COV2

    go.drugbank.com/drugs/DB16428
    Investigational

    GRAd-COV2 is a COVID-19 vaccine candidate being developed by ReiThera[L30420, L30423].

  8. Drug

    BB-301

    go.drugbank.com/drugs/DB17011
    Investigational

    [A260112] Developed by Benitec Biopharma, BB-301 is being investigated for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD).[L47062]

  9. Drug

    Enlonstobart

    go.drugbank.com/drugs/DB21890
    Investigational

    [A274486] It targets the programmed cell death protein 1 (PD-1), is being developed by the CSPC Pharmaceutical Group for the treatment of advanced cervical cancer and other solid tumours.

  10. Drug

    Arsthinol

    go.drugbank.com/drugs/DB08928
    Experimental

    Arsthinol (INN) is an antiprotozoal agent that was first synthesized by Ernst A.H. Friedheim in 1949 via the complexing of acetarsol with 2,3-dimercaptopropanol.